Recurrent angiosarcoma is one of the most challenging situations for both patients and their medical teams. This rare and aggressive cancer, which originates in the cells lining blood vessels or lymph vessels, has a well-known tendency to return even after seemingly successful treatment. Understanding how recurrence is managed, what treatments are currently used, and what new therapies are being tested in clinical trials can help patients and their families navigate this difficult journey with greater confidence and hope.

Fighting Back When Cancer Returns

When angiosarcoma comes back after initial treatment, the situation becomes more complex. This type of cancer is known for its aggressive behavior and high recurrence rate, with approximately 75% of recurrences happening within the first two years after local treatment.^[1] The cancer’s tendency to infiltrate surrounding tissues extensively makes it difficult to remove completely during surgery, and cancer cells that remain or spread to distant organs can lead to the disease returning, sometimes in the same location or in new areas such as the lungs, liver, or bones.^[2]

The goals of treating recurrent angiosarcoma depend greatly on where the cancer has returned, how much it has spread, and the patient’s overall health. For some patients, the aim may be to control the disease and slow its progression, while for others, treatment focuses on managing symptoms and maintaining the best possible quality of life. Medical teams typically tailor their approach based on whether the recurrence is localized (meaning it has returned in or near the original site) or whether it has spread to distant parts of the body.^[3]

Recurrent angiosarcoma presents unique challenges because the disease may behave differently than it did initially. Some tumors may have changed in ways that make them more resistant to treatments that worked before. This is why a comprehensive approach, often involving multiple specialists working together, is essential. The treatment team might include surgeons, medical oncologists who specialize in chemotherapy, radiation oncologists, and specialists in new therapeutic approaches being tested in research settings.^[4]

Standard Treatment Approaches for Recurrent Disease

The standard treatment for recurrent angiosarcoma depends heavily on the pattern of recurrence. When the cancer returns in a localized area and has not spread elsewhere, surgery may once again be considered. The surgeon’s goal is to remove the tumor along with a margin of normal tissue around it to ensure all cancer cells are eliminated. However, achieving complete removal can be extremely challenging with recurrent angiosarcoma, particularly when the tumor has returned in the head and neck region where important structures limit how much tissue can safely be removed.^[5]

For patients whose angiosarcoma has recurred in the same area after previous surgery, the decision to operate again must be carefully weighed. The surgery may be more extensive than the first operation, and in some cases, it may not be possible to achieve clear margins (meaning tumor-free edges) without causing unacceptable loss of function or appearance. In such situations, combining surgery with other treatments becomes particularly important.^[6]

Chemotherapy, which uses drugs to kill cancer cells throughout the body, plays a central role in managing recurrent angiosarcoma, especially when the disease has spread to distant sites. Several chemotherapy drugs have shown activity against angiosarcoma. Paclitaxel, a drug that belongs to a class called taxanes, has proven to be particularly effective. It is typically given weekly through an intravenous infusion. Medical studies have shown that paclitaxel is well tolerated even in patients who have already received other chemotherapy treatments, and it can help slow tumor growth and improve symptoms.^[7]

Another important group of chemotherapy drugs used for recurrent angiosarcoma are anthracyclines, which include doxorubicin and epirubicin. These medications work by interfering with the DNA inside cancer cells, preventing them from dividing and growing. Doxorubicin can be used alone or in combination with other drugs such as dacarbazine or ifosfamide. While anthracycline-based regimens can be effective, they do carry a risk of side effects, including damage to the heart muscle with prolonged use, so doctors carefully monitor patients receiving these treatments.^[8]

Combination chemotherapy regimens that pair gemcitabine with other drugs such as docetaxel, vinorelbine, or dacarbazine represent another standard approach. Gemcitabine interferes with DNA synthesis in cancer cells, and when combined with docetaxel, it has shown response rates ranging from 40% to 50% in patients with advanced or metastatic angiosarcoma. These combination treatments tend to be more effective than single drugs but also come with increased side effects, including lowered blood cell counts, fatigue, and increased risk of infections.^[9]

The duration of chemotherapy treatment varies based on how well the cancer responds and how well the patient tolerates the medication. Some patients may receive chemotherapy for several months, while others might continue treatment for longer periods if the cancer is being controlled and side effects remain manageable. Common side effects of chemotherapy can include nausea, hair loss, fatigue, mouth sores, increased vulnerability to infections due to low white blood cell counts, and numbness or tingling in the hands and feet (a condition called peripheral neuropathy).^[10]

Radiation therapy, which uses high-energy beams to destroy cancer cells, is another cornerstone of treatment for recurrent angiosarcoma. It can be particularly valuable when the cancer has returned in a localized area. Radiation therapy works by damaging the DNA within cancer cells, preventing them from dividing. It is typically delivered in multiple sessions over several weeks, with each treatment lasting only a few minutes.^[11]

However, radiation therapy for recurrent angiosarcoma presents a unique challenge. Many patients with recurrent disease had radiation therapy as part of their initial treatment, and there are limits to how much radiation a particular area of the body can safely receive over a lifetime. Exceeding these limits can cause serious damage to normal tissues. For patients who have already received the maximum safe dose of radiation to an area, additional radiation may not be an option. In some cases, physicians may use specialized radiation techniques that can more precisely target the tumor while sparing surrounding normal tissue.^[12]

Side effects of radiation therapy depend on the area being treated and can include skin changes that resemble sunburn, fatigue, and in the case of head and neck treatment, hair loss in the treated area, mouth sores, or difficulty swallowing. These effects usually improve after treatment ends, although some may persist or develop months to years later.^[13]

Promising Therapies Being Tested in Clinical Trials

Because standard treatments for recurrent angiosarcoma have limited effectiveness and the disease often continues to progress, researchers around the world are actively testing new approaches in clinical trials. These studies are crucial for advancing our understanding of angiosarcoma and potentially finding more effective treatments.

Targeted therapy represents one of the most promising areas of research for recurrent angiosarcoma. These treatments are designed to attack specific molecular features of cancer cells while causing less harm to normal cells. One of the most important targets in angiosarcoma is the pathway that controls blood vessel formation, since these tumors originate from blood vessel cells and often show abnormal activity in genes that regulate blood vessel growth.^[14]

Pazopanib is a targeted drug that has shown promise in clinical trials for patients with recurrent or metastatic angiosarcoma. This medication works by blocking several proteins called tyrosine kinases that are involved in tumor growth and blood vessel formation. These proteins include VEGFR (vascular endothelial growth factor receptor), which plays a key role in creating new blood vessels that feed tumors. In a retrospective study of patients with advanced angiosarcoma who had already received standard chemotherapy, pazopanib demonstrated activity with some patients experiencing tumor shrinkage. The median time before disease progression was approximately three months, and median overall survival was about 10 months.^[15]

Research has identified specific genetic changes in angiosarcoma that may help guide treatment decisions. Studies using advanced genetic sequencing have found recurrent mutations in genes including KDR (which codes for VEGFR2), TP53, and PIK3CA. Interestingly, the pattern of genetic changes can differ depending on where the angiosarcoma developed and what caused it. For example, angiosarcomas of the scalp, face, and neck that developed without prior radiation show a high number of mutations consistent with damage from ultraviolet light, suggesting that sun exposure may play a role in some cases. This finding has important implications because it suggests these tumors might respond to immunotherapy, a treatment that helps the body’s immune system recognize and attack cancer cells.^[16]

Immunotherapy using drugs that block a protein called PD-1 (programmed death-1) or its partner PD-L1 represents an exciting frontier in angiosarcoma treatment. These proteins normally act as “brakes” on the immune system, preventing it from attacking the body’s own cells. However, cancer cells often hijack this system by expressing PD-L1, which binds to PD-1 on immune cells and effectively hides the cancer from immune attack. Drugs that block this interaction, such as pembrolizumab and nivolumab, can release these brakes and allow the immune system to fight the cancer.^[17]

A case report published in a medical journal described a remarkable response in a patient with recurrent angiosarcoma who was treated with pembrolizumab. The patient’s tumor expressed PD-L1, and after receiving pembrolizumab every three weeks, he experienced marked shrinkage of liver disease and no new facial lesions. Although the patient developed hepatitis as a side effect (an inflammatory condition of the liver that required treatment with steroids), after stopping pembrolizumab, he remained free of cancer progression for eight months. This case demonstrates that some patients with recurrent angiosarcoma may benefit significantly from immunotherapy, particularly if their tumors express PD-L1.^[18]

Another innovative approach being studied involves combining propranolol, a medication traditionally used to treat high blood pressure and heart conditions, with low-dose chemotherapy drugs. Propranolol is a beta-blocker that may help fight cancer by blocking signals that promote blood vessel formation and tumor growth. In a small study of patients with advanced angiosarcoma, combining propranolol (40 mg twice daily) with weekly low doses of vinblastine and methotrexate led to responses in all seven patients treated, including one complete response where the cancer could no longer be detected. The median time before disease progression was 11 months, and median overall survival was 16 months. Based on these encouraging results, propranolol received orphan drug status in Europe for soft tissue sarcoma treatment, and further studies are ongoing.^[19]

Clinical trials testing these new therapies typically proceed through three phases. Phase I trials focus primarily on determining the safe dose of a new treatment and identifying potential side effects. These studies usually enroll a small number of patients. Phase II trials test whether the treatment is effective at fighting the cancer, looking for tumor shrinkage or slowed growth. Phase III trials compare the new treatment directly with standard therapy to determine if it offers better outcomes. Patients with recurrent angiosarcoma may be eligible for trials in any of these phases, depending on their specific situation and the availability of trials at medical centers near them or at specialized cancer centers in the United States, Europe, and other parts of the world.^[20]

Eligibility for clinical trials typically requires that patients meet certain criteria, which may include having confirmed angiosarcoma that has recurred or spread, having adequate organ function (particularly of the heart, liver, and kidneys), and being well enough to tolerate the investigational treatment. Some trials specifically seek patients whose tumors have particular genetic characteristics, such as specific gene mutations or expression of certain proteins like PD-L1. Patients interested in clinical trials should discuss this option with their oncology team, who can help identify appropriate studies.^[21]

The combination of multiple treatment approaches—sometimes called multimodality therapy—has shown promise in extending survival for patients with recurrent angiosarcoma. One case report described a 66-year-old man with scalp angiosarcoma that had recurred and spread to multiple organs. He received combination chemotherapy with cyclophosphamide, epirubicin, vincristine, and dacarbazine as first-line treatment, achieving a complete response (meaning no detectable cancer) that lasted eight months. When the cancer returned again, he benefited from additional comprehensive treatment including various chemotherapy drugs, radiation therapy, and anti-angiogenic therapy (treatment that blocks blood vessel formation). His overall survival reached 38 months from initial diagnosis, which is considered favorable for this aggressive disease. This case illustrates how combining different treatment approaches and adjusting therapy as the disease changes can potentially extend survival and maintain quality of life.^[22]

Most common treatment methods

• Surgery
  • Surgical removal of recurrent tumor with aim to achieve clear margins of normal tissue
  • May be combined with radiation therapy and chemotherapy
  • Can be challenging for head and neck recurrences due to proximity to vital structures
• Chemotherapy with taxanes
  • Paclitaxel given weekly through intravenous infusion
  • Well tolerated even in previously treated patients
  • Can help slow tumor growth and improve symptoms
• Anthracycline-based chemotherapy
  • Doxorubicin or epirubicin, used alone or in combination with dacarbazine or ifosfamide
  • Interferes with cancer cell DNA to prevent division
  • Requires heart monitoring due to potential cardiac effects
• Gemcitabine combination therapy
  • Gemcitabine combined with docetaxel, vinorelbine, or dacarbazine
  • Response rates of 40-50% in advanced disease
  • Common side effects include lowered blood counts and fatigue
• Radiation therapy
  • Uses high-energy beams to destroy cancer cells
  • Typically delivered over multiple sessions spanning several weeks
  • May be limited in recurrent disease if maximum safe dose was given previously
• Targeted therapy
  • Pazopanib blocks proteins involved in tumor growth and blood vessel formation
  • Targets VEGFR and other tyrosine kinases
  • Tested in patients who have already received standard chemotherapy
• Immunotherapy
  • Pembrolizumab and nivolumab block PD-1/PD-L1 interaction
  • Helps immune system recognize and attack cancer cells
  • May be particularly effective in tumors expressing PD-L1 or with high mutation burden
• Combination therapy with propranolol
  • Beta-blocker propranolol combined with low-dose vinblastine and methotrexate
  • May block signals promoting blood vessel formation
  • Investigated in clinical studies with promising early results